Company Filing History:
5 out of 109 
3 out of 1,454 
2 out of 138 
Years Active: 2018-2024
Title: The Innovative Contributions of Jean Keyaerts
Introduction
Jean Keyaerts is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on fused pentacyclic imidazole derivatives. With a total of seven patents to his name, Keyaerts has established himself as a key figure in the development of treatments for various human ailments.
Latest Patents
Keyaerts' latest patents focus on a series of fused pentacyclic imidazole derivatives. These compounds are recognized as potent modulators of human TNFa activity, which is crucial in the treatment and prevention of a wide range of human ailments. These include autoimmune and inflammatory disorders, neurological and neurodegenerative disorders, pain and nociceptive disorders, cardiovascular disorders, metabolic disorders, ocular disorders, and oncological disorders. Specifically, his inventions concern 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and their analogs.
Career Highlights
Throughout his career, Keyaerts has worked with prominent companies in the pharmaceutical industry, including UCB Biopharma and Sanofi. His work in these organizations has allowed him to collaborate with leading experts and contribute to groundbreaking research in drug development.
Collaborations
Keyaerts has collaborated with notable colleagues such as Jag Paul Heer and Mark Daniel Calmiano. These partnerships have further enhanced his research and innovation capabilities.
Conclusion
Jean Keyaerts is a distinguished inventor whose work has the potential to impact the treatment of various serious health conditions. His innovative patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.